Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. 2010

Michael Schäfers, and Otmar Schober, and Sven Hermann
European Institute for Molecular Imaging-EIMI, Münster, Germany. schafmi@uni-muenster.de

Cardiovascular events such as myocardial infarction or stroke resulting from atherosclerosis still account for the majority of deaths worldwide. New imaging approaches focusing on the visualization of inflammation in the vessel wall may emerge as tools for individualized risk assessment and prevention of events. Enzymes such as matrix-metalloproteinases (MMPs) are involved in several steps in plaque progression driving plaques into vulnerable, rupture-prone states. Targeting of MMPs for imaging is therefore a promising strategy. The rationale, potential, and current status of imaging MMPs in the clinical context of stroke and myocardial infarction are reviewed here from a clinical viewpoint.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses
D057054 Molecular Imaging The use of molecularly targeted imaging probes to localize and/or monitor biochemical and cellular processes via various imaging modalities that include RADIONUCLIDE IMAGING; ULTRASONOGRAPHY; MAGNETIC RESONANCE IMAGING; FLUORESCENCE IMAGING; and MICROSCOPY. Imaging, Molecular
D061965 Matrix Metalloproteinase Inhibitors Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES. Collagenase Inhibitor,Gelatinase Inhibitor,MMP Inhibitor,Matrix Metalloproteinase Inhibitor,Collagenase Inhibitors,Gelatinase Inhibitors,MMP Inhibitors,Stromelysin Inhibitors,Inhibitor, Collagenase,Inhibitor, Gelatinase,Inhibitor, MMP,Inhibitor, Matrix Metalloproteinase,Inhibitors, Collagenase,Inhibitors, Gelatinase,Inhibitors, MMP,Inhibitors, Matrix Metalloproteinase,Inhibitors, Stromelysin,Metalloproteinase Inhibitor, Matrix,Metalloproteinase Inhibitors, Matrix
D020782 Matrix Metalloproteinases A family of zinc-dependent metalloendopeptidases that is involved in the degradation of EXTRACELLULAR MATRIX components. MMP,MMPs,Matrix Metalloproteinase,Metalloproteinase, Matrix,Metalloproteinases, Matrix

Related Publications

Michael Schäfers, and Otmar Schober, and Sven Hermann
March 2012, Thrombosis and haemostasis,
Michael Schäfers, and Otmar Schober, and Sven Hermann
July 1999, Neurology,
Michael Schäfers, and Otmar Schober, and Sven Hermann
December 1994, The Journal of clinical investigation,
Michael Schäfers, and Otmar Schober, and Sven Hermann
January 2004, Cardiology in review,
Michael Schäfers, and Otmar Schober, and Sven Hermann
October 2015, Brain research,
Michael Schäfers, and Otmar Schober, and Sven Hermann
November 2007, Trends in cardiovascular medicine,
Michael Schäfers, and Otmar Schober, and Sven Hermann
November 1998, Arteriosclerosis, thrombosis, and vascular biology,
Michael Schäfers, and Otmar Schober, and Sven Hermann
January 2007, Current pharmaceutical design,
Copied contents to your clipboard!